Recursion's First Clinical Validation of AI-Enabled Platform with Rare Disease Drug REC-4881

Recursion in JavaScript and Tail Calls #javascript #recursion #tailcalls

Recursion on Instagram: "🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and require